Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma

Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with poor long-term survival. This study assessed methotrexate (MTX) plus idarubicin (IDA) in treating patients of PCNSL comparing to MTX alone therapy. A total of 100 patients were retrospectively enrolled and su...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Ni, Zhang, Lu, Xu, Xiaoping, Chen, Bobin, Zhu, Chen, Li, Pei, Chen, Zi, Ding, Tianling, Ma, Yan, Yuan, Yan, Lin, Zhiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581143/
https://www.ncbi.nlm.nih.gov/pubmed/28881844
http://dx.doi.org/10.18632/oncotarget.15899
_version_ 1783261008929751040
author Fan, Ni
Zhang, Lu
Xu, Xiaoping
Chen, Bobin
Zhu, Chen
Li, Pei
Chen, Zi
Ding, Tianling
Ma, Yan
Yuan, Yan
Lin, Zhiguang
author_facet Fan, Ni
Zhang, Lu
Xu, Xiaoping
Chen, Bobin
Zhu, Chen
Li, Pei
Chen, Zi
Ding, Tianling
Ma, Yan
Yuan, Yan
Lin, Zhiguang
author_sort Fan, Ni
collection PubMed
description Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with poor long-term survival. This study assessed methotrexate (MTX) plus idarubicin (IDA) in treating patients of PCNSL comparing to MTX alone therapy. A total of 100 patients were retrospectively enrolled and subjected to MTX alone (n = 52) and MTX plus IDA (n = 48). The completed response (CR) rate in patients treated with MTX plus IDA was 62.50%, and overall response (OR) rate was 79.17%, which in MTX alone cohort were 42.31% and 63.46% respectively. Median progression-free survival (PFS) of patients treated with MTX plus IDA was significantly better than those treated with MTX alone (18.35 months vs.8.45months, P = 0.000). The MTX plus IDA regimen exhibited a significantly better control of PCNSL. Further studies would be needed to confirm these results.
format Online
Article
Text
id pubmed-5581143
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55811432017-09-06 Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma Fan, Ni Zhang, Lu Xu, Xiaoping Chen, Bobin Zhu, Chen Li, Pei Chen, Zi Ding, Tianling Ma, Yan Yuan, Yan Lin, Zhiguang Oncotarget Clinical Research Paper Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with poor long-term survival. This study assessed methotrexate (MTX) plus idarubicin (IDA) in treating patients of PCNSL comparing to MTX alone therapy. A total of 100 patients were retrospectively enrolled and subjected to MTX alone (n = 52) and MTX plus IDA (n = 48). The completed response (CR) rate in patients treated with MTX plus IDA was 62.50%, and overall response (OR) rate was 79.17%, which in MTX alone cohort were 42.31% and 63.46% respectively. Median progression-free survival (PFS) of patients treated with MTX plus IDA was significantly better than those treated with MTX alone (18.35 months vs.8.45months, P = 0.000). The MTX plus IDA regimen exhibited a significantly better control of PCNSL. Further studies would be needed to confirm these results. Impact Journals LLC 2017-03-04 /pmc/articles/PMC5581143/ /pubmed/28881844 http://dx.doi.org/10.18632/oncotarget.15899 Text en Copyright: © 2017 Fan et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Clinical Research Paper
Fan, Ni
Zhang, Lu
Xu, Xiaoping
Chen, Bobin
Zhu, Chen
Li, Pei
Chen, Zi
Ding, Tianling
Ma, Yan
Yuan, Yan
Lin, Zhiguang
Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
title Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
title_full Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
title_fullStr Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
title_full_unstemmed Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
title_short Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
title_sort methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581143/
https://www.ncbi.nlm.nih.gov/pubmed/28881844
http://dx.doi.org/10.18632/oncotarget.15899
work_keys_str_mv AT fanni methotrexateplusidarubicinimprovesoutcomeofpatientswithprimarycentralnervoussystemlymphoma
AT zhanglu methotrexateplusidarubicinimprovesoutcomeofpatientswithprimarycentralnervoussystemlymphoma
AT xuxiaoping methotrexateplusidarubicinimprovesoutcomeofpatientswithprimarycentralnervoussystemlymphoma
AT chenbobin methotrexateplusidarubicinimprovesoutcomeofpatientswithprimarycentralnervoussystemlymphoma
AT zhuchen methotrexateplusidarubicinimprovesoutcomeofpatientswithprimarycentralnervoussystemlymphoma
AT lipei methotrexateplusidarubicinimprovesoutcomeofpatientswithprimarycentralnervoussystemlymphoma
AT chenzi methotrexateplusidarubicinimprovesoutcomeofpatientswithprimarycentralnervoussystemlymphoma
AT dingtianling methotrexateplusidarubicinimprovesoutcomeofpatientswithprimarycentralnervoussystemlymphoma
AT mayan methotrexateplusidarubicinimprovesoutcomeofpatientswithprimarycentralnervoussystemlymphoma
AT yuanyan methotrexateplusidarubicinimprovesoutcomeofpatientswithprimarycentralnervoussystemlymphoma
AT linzhiguang methotrexateplusidarubicinimprovesoutcomeofpatientswithprimarycentralnervoussystemlymphoma

Ejemplares similares